Navigation Links
Equashield's Sales Grow by 60% in 2013
Date:1/14/2014

PORT WASHINGTON, New York, January 14, 2014 /PRNewswire/ --

Equashield (http://www.equashield.com), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced that it has achieved 60% year-over-year sales growth for the fourth straight year.  

Equashield's closed systems reduce the risk of exposure for pharmacy technicians, pharmacists, nurses and other medical professionals who prepare and administer hazardous drugs, such as chemotherapy. In addition, the solution helps to prevent microbial ingress, decreasing the risk of infection in patients receiving these drugs.

"Approximately 20% of hospitals and medical centers are already investing in closed systems to ensure their employees' safety," said Marino Kriheli, Product Manager at Equashield. "With growing awareness of the many risks associated with hazardous drug exposure, this market is rapidly growing. In fact, 55% of new customers Equashield acquired this year did not use closed systems previously. Furthermore, with the recent launch of Equashield II, the company's second generation CSTD, we expect major sales growth to continue in 2014 and beyond."

Equashield is the only preassembled closed syringe that requires no further setup, making it quicker and easier to use than other system on the market. Equashield devices are currently used in the Cleveland Clinic, Mt. Sinai Hospital in New York and hundreds of other medical facilities.

Equashield II covers more routes of exposure to hazardous drugs than alternative systems and is the only system that prevents contamination of syringe plungers by hazardous drugs.

"Contamination on syringe plungers has been clearly identified in recent studies, added Kriheli. "The quantities of drug residue found on plungers place this route of exposure among the top risks associated with handling hazardous drugs."

About Equashield

Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® provides superior safety & ease-of-use by covering more routes of exposure than alternative systems and by enabling faster use than other systems. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residue even after multiple connections. EQUASHIELD® is the only preassembled CSTD syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit http://www.equashield.com.

Media Contact:
Finn Partners for Equashield
Ellie Hanson
ellie@finnpartners.co.il
+972-54-467-6980


'/>"/>
SOURCE Equashield
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
2. AMRI Hires George Svokos as Senior Vice President Sales and General Manager - API
3. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
4. Simbionix Welcomes New Latin and Central American Sales Manager
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. TRU-D SmartUVC Sales Soar in 2013 with Increased Acceptance of Proven Infection Prevention Technology
7. Indegene Named a Leader in IDC MarketScape: Worldwide Life Science Sales and Marketing BPO 2013 Vendor Assessment
8. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
9. The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022
10. Osseon Announces New Regional Sales Director
11. Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):